Your browser is no longer supported. Please, upgrade your browser.
Settings
THOR Synthorx, Inc. daily Stock Chart
THOR [NASD]
Synthorx, Inc.
Index- P/E- EPS (ttm)-1.93 Insider Own2.10% Shs Outstand32.32M Perf Week-0.16%
Market Cap2.20B Forward P/E- EPS next Y-1.48 Insider Trans0.00% Shs Float29.45M Perf Month0.25%
Income-63.60M PEG- EPS next Q-0.43 Inst Own86.00% Short Float1.24% Perf Quarter392.32%
Sales- P/S- EPS this Y-831.80% Inst Trans0.01% Short Ratio0.90 Perf Half Y330.32%
Book/sh4.78 P/B14.22 EPS next Y3.90% ROA-35.60% Target Price59.75 Perf Year353.57%
Cash/sh4.67 P/C14.56 EPS next 5Y- ROE-37.80% 52W Range11.05 - 71.90 Perf YTD-2.72%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-5.44% Beta-
Dividend %- Quick Ratio18.90 Sales past 5Y- Gross Margin- 52W Low515.29% ATR0.70
Employees48 Current Ratio18.90 Sales Q/Q- Oper. Margin- RSI (14)76.03 Volatility0.24% 1.18%
OptionableYes Debt/Eq0.00 EPS Q/Q47.80% Profit Margin- Rel Volume1.77 Prev Close67.99
ShortableYes LT Debt/Eq0.00 EarningsFeb 04 AMC Payout- Avg Volume403.25K Price67.99
Recom2.70 SMA20-1.91% SMA5040.39% SMA200185.39% Volume0 Change0.00%
Dec-19-19Downgrade Jefferies Buy → Hold $68
Dec-11-19Downgrade SVB Leerink Outperform → Mkt Perform
Dec-10-19Downgrade H.C. Wainwright Buy → Neutral
Jan-02-19Initiated Jefferies Buy $21
Jan-02-19Initiated H.C. Wainwright Buy $30
Jan-09-20 01:15PM  IBKC, THOR, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
10:15AM  INVESTOR ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Transaction ACCESSWIRE
Jan-07-20 02:00PM  READ NOW: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Merger ACCESSWIRE
09:00AM  INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - INST, THOR, LOGM ACCESSWIRE
12:00AM  WAAS, TIVO, THOR, and CRCM SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
Jan-06-20 02:05PM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - HABT, INST, THOR ACCESSWIRE
11:07AM  Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm PR Newswire
Jan-03-20 01:00PM  STOCKHOLDER ALERT: Monteverde & Associates PC Remind Investors of its Ongoing Investigation Regarding the Acquisition ACCESSWIRE
Jan-02-20 06:30PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: CBPX, BOLD, THOR ACCESSWIRE
03:00PM  CBB, TGE, INST, and THOR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
Dec-31-19 12:00PM  STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of an Ongoing Inquiry Regarding the Buyout ACCESSWIRE
Dec-30-19 06:15PM  MERGER ALERT - WAAS, THOR, and TGE: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
06:48AM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR ACCESSWIRE
Dec-28-19 02:00PM  THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
Dec-27-19 04:30PM  STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Inquiry Regarding the Acquisition ACCESSWIRE
08:47AM  Can Winnebago Replicate This Year's Stellar Show in 2020? Zacks
Dec-24-19 01:09PM  Why A Bidding War For Synthorx Bodes Well For This Biotech Stock Investor's Business Daily
12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
11:05AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - THOR, ARQL, LOGM ACCESSWIRE
Dec-23-19 06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR ACCESSWIRE
04:12PM  Pharma M&A Deals Likely To Be Smaller in 2020 GuruFocus.com
09:00AM  INST, THOR, AMTD, and AKS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts GlobeNewswire
08:34AM  Moving Average Crossover Alert: Synthorx Zacks
Dec-21-19 11:44AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders BOLD, INST, THOR GlobeNewswire
Dec-18-19 06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Reminds Investors of Investigations Related to the Following Companies: ARQL, BOLD, THOR ACCESSWIRE
Dec-17-19 04:39PM  Hedge Funds Have Never Been More Bullish On Synthorx, Inc. (THOR) Insider Monkey
Dec-16-19 11:15AM  SHAREHOLDER ALERT: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Merger ACCESSWIRE
11:00AM  MERGER ALERT - THOR and INST: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
08:00AM  SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders BOLD, AKS, INST, THOR GlobeNewswire
Dec-13-19 04:20PM  STOCKHOLDER ALERT: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Acquisition ACCESSWIRE
12:15PM  MERGER ALERT - THOR and INST: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies ACCESSWIRE
Dec-12-19 04:15PM  READ NOW: Monteverde & Associates PC Reminds Investors of its Ongoing Investigation Regarding the Buyout ACCESSWIRE
01:41PM  Theres more upside for biotech even after 24% gains in two months MarketWatch
01:19PM  SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers GlobeNewswire
Dec-11-19 03:15PM  URGENT NEWS: Monteverde & Associates PC Continues its Legal Inquiry for the Recent Buyout ACCESSWIRE
Dec-10-19 06:45PM  SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Synthorx, Inc. - (NasdaqGS: THOR) ACCESSWIRE
04:16PM  Why Biotech ETFs are Surging to New Highs Zacks
11:56AM  SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of SYNTHORX, INC. - THOR PR Newswire
10:10AM  Biotech ETFs Hit New Highs on Deal Activities Zacks
09:07AM  Company News for Dec 10, 2019 Zacks
08:55AM  Sanofi Unveils Growth Strategy, Ends Diabetes & CV Research Zacks
08:27AM  Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms Zacks
07:56AM  The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares Benzinga
07:14AM  Drug manufacturers have spent a record $342 billion on M&A in 2019 MarketWatch
06:38AM  Sanofis CEO Quits Diabetes as Cancer Breakthroughs Beckon Bloomberg
Dec-09-19 06:49PM  Flagging French Drug Giant Tries a Familiar Remedy Bloomberg +170.52%
04:45PM  U.S. stock market snaps 3-day win streak as China tariff deadline comes in focus MarketWatch
04:44PM  Sanofis New CEO Is Aiming for a Narrower Focus in Drug Development Barrons.com
12:52PM  SYNTHORX ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of THOR and Encourages Investors to Contact the Firm PR Newswire
12:15PM  SYNTHORX, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout ACCESSWIRE
11:56AM  Synthorx Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Synthorx, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm THOR GlobeNewswire
11:04AM  Heres the hard-money call for why the boom in the economy and stock market will continue MarketWatch
10:44AM  Drug Giants Pay Hefty Premiums as Cancer-Drug Race Heats Up Bloomberg
10:16AM  Week Begins with Biotech Mergers Zacks
10:06AM  Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More Zacks
09:42AM  Merck and Sanofi Are Both Acquiring Cancer-Drug Developers Barrons.com
09:28AM  Sanofi to Buy Synthorx for $2.5B to Boost Cancer Portfolio Zacks
07:53AM  Synthorx To Be Acquired By Sanofi For $2.5B Benzinga
07:43AM  Sanofi and Merck each buy cancer-focused biotechs Financial Times
07:23AM  No News Is Bad News As Dow Set For Lower Start Barrons.com
07:06AM  Sanofi to Buy U.S. Biotech Firm for $2.5 Billion in Cancer Push Bloomberg
06:06AM  European Stocks Are Struggling In the Week of the ECBs Last Meeting of the Year Barrons.com
05:30AM  European stocks struggle, with drugmakers weaker and Tullow Oil plunging MarketWatch
04:48AM  Sanofi to Buy Synthorx for $2.5 Billion Bloomberg
04:07AM  Sanofi to acquire Synthorx for $2.5 billion MarketWatch
03:52AM  France's Sanofi to buy biotech firm Synthorx for $2.5 billion Reuters
03:11AM  UPDATE 2-France's Sanofi to buy biotech firm Synthorx for $2.5 bln Reuters
01:38AM  France's Sanofi to buy Synthorx for $2.5 billion Reuters
01:38AM  France's Sanofi to buy biotech firm Synthorx for $2.5 billion Reuters
01:32AM  France's Sanofi to buy Synthorx for $2.5 bln Reuters
Nov-14-19 05:30AM  Will Synthorx Continue to Surge Higher? Zacks
Nov-13-19 08:00AM  Synthorx to Present at Upcoming Investor Conferences GlobeNewswire
Nov-05-19 04:05PM  Synthorx Reports Third Quarter Financial Results GlobeNewswire +8.81%
08:00AM  Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting GlobeNewswire
Oct-31-19 02:19PM  Hedge Funds Have Never Been This Bullish On Synthorx, Inc. (THOR) Insider Monkey
Oct-29-19 04:05PM  Synthorx to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire +13.32%
Sep-23-19 08:00AM  Synthorx to Present at the European Society for Medical Oncology (ESMO) 2019 Congress GlobeNewswire
Sep-19-19 12:54PM  How Long Will Synthorx, Inc.'s (NASDAQ:THOR) Cash Last? Simply Wall St.
Sep-09-19 08:00AM  Synthorx to Present at the 2019 World Congress of Inflammation GlobeNewswire
Aug-29-19 04:05PM  Synthorx to Present at H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire
Jul-24-19 08:00AM  Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707 GlobeNewswire
Jul-19-19 07:52AM  Synthorx's Shares March Higher, Can It Continue? Zacks
May-29-19 04:10PM  Synthorx to Present at Jefferies 2019 Healthcare Conference GlobeNewswire -5.50%
May-15-19 05:15PM  Synthorx to Present at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
Apr-30-19 05:49PM  Synthorx: 1Q Earnings Snapshot Associated Press -5.96%
04:05PM  Synthorx Reports First Quarter Financial Results GlobeNewswire
Apr-23-19 07:00AM  3 Top Stocks That Aren't on Wall Street's Radar Motley Fool
Apr-02-19 08:00AM  Synthorx to Present at H.C. Wainwright Global Life Sciences Conference in London GlobeNewswire
Mar-19-19 08:00AM  Synthorx to Present at the American Association of Cancer Research (AACR) Annual Meeting 2019 GlobeNewswire
Mar-12-19 05:38PM  Synthorx: 4Q Earnings Snapshot Associated Press
04:05PM  Synthorx Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
08:00AM  Synthorx to Present at the Chinese Society for Clinical Oncology Conference on Immunotherapy GlobeNewswire
Feb-25-19 12:41PM  Small Cap Winners And Losers From Last Week Benzinga
Feb-21-19 04:05PM  Synthorx to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire -9.89%
Dec-20-18 08:00AM  Synthorx Appoints Andrew Powell, J.D., to its Board of Directors GlobeNewswire
Dec-12-18 04:05PM  Synthorx Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +9.73%
Dec-06-18 09:15PM  Synthorx Announces Pricing of Initial Public Offering GlobeNewswire
04:00PM  Stocks pare losses, Nasdaq closes in the green Yahoo Finance
Dec-02-18 05:01PM  IPO Outlook For The Week: Proteins, Fashion And Finance Benzinga
Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Leveque JosephChief Medical OfficerDec 30Option Exercise11.0075,000825,000358,910Jan 02 04:43 PM
Milla MarcosChief Scientific OfficerDec 30Option Exercise0.6398,00061,740116,000Jan 02 04:41 PM
Shawver LauraPresident and CEODec 30Option Exercise4.02379,4531,525,319506,311Jan 02 04:39 PM